cue-102
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 14, 2022 (NCT05360680)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Wilms tumor proteinBINDING AGENT
binding agent - wt1
Chemistry & pharmacology
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06917885 | Phase 1 | Jul 30, 2025 | Cue Biopharma, Harvard University |
| NCT05360680 | Phase 1 | Jun 14, 2022 | Cue Biopharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cue Biopharma | For profit | 2 | 1 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1